Objectives: Incidental cerebral microhemorrhage (MH) is frequently found in older individuals scanned with susceptibility-weighted MRI (SWI) or gradient-recalled echo MRI. MH have been linked with ␤-amyloid (A␤) deposition using 11 C-Pittsburgh compound B (PiB) PET in Alzheimer disease (AD) and cerebral amyloid angiopathy (CAA). We hypothesized that A␤ deposition in asymptomatic elderly individuals is associated with lobar MH (LMH).
associated with impaired cognition in otherwise healthy controls, 19 ICH survivors, 18 and reduced survival in memory clinic attendees. 20 In AD, MH may be relevant to both the manifestation and progression of symptoms, and have also been implicated in complications of AD immunotherapy, particularly in APOE ⑀4 carriers. 21, 22 PET using 11 C-Pittsburgh compound B (PiB) has been used to detect fibrillar A␤ deposition in AD, other neurodegenerative diseases, and in cognitively normal older individuals. 23 Using 11 C-PiB, A␤ deposition has been shown in patients with CAAassociated hemorrhage, 24, 25 with hemorrhage post-thrombolysis for ischemic stroke, 26 and topographically, in brain parenchyma corresponding to MH seen with MRI. 27 This study was performed to assess whether cerebral A␤ deposition is also associated with increased risk of lobar MH (LMH) in asymptomatic individuals.
METHODS Study population. Participants of this study
were recruited from the Melbourne arm of the Australian Imaging, Biomarkers and Lifestyle Study of Ageing (AIBL). All participants underwent SWI MRI, 11 C-PiB PET scan, and blood drawn for biomarkers and APOE ⑀4 genotype sequencing. A total of 138 participants were included in this study: 26 patients with AD, 28 patients with mild cognitive impairment (MCI), and 84 elderly healthy controls (HC). Medical history was obtained from participants or carers, including prescribed antiplatelet or anticoagulant therapy. Vascular risk factors were identified using self-report, physical examination, and laboratory findings: hypertension, hypercholesterolemia, diabetes, current smoking history, atrial fibrillation, prior or current history of vascular disease (coronary or peripheral vascular disease), and dichotomized as present or absent according to published guidelines. Participants with current or past history of stroke were excluded. 28 Subjects with MCI met Petersen criteria of subjective and objective cognitive difficulties, predominantly affecting memory, in the absence of dementia or significant functional loss. 29
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PET neuroimaging protocol. Each subject received ϳ370
MBq 11 C-PiB IV over 1 minute. 18 A 30-minute acquisition, starting 40 minutes after injection of 11 C-PiB, was performed using a Phillips Allegro™ PET camera. A transmission scan was performed for attenuation correction. Cortical-to-cerebellar gray matter ratios (standardized uptake value ratio [SUVR]) were generated for regions of interest. Neocortical A␤-burden (neocortical SUVR) was expressed as the average SUVR of the areaweighted mean of frontal, superior parietal, lateral temporal, lateral occipital, and anterior and posterior cingulate regions. In addition to quantitative analysis, PiB images were read by a nuclear medicine physician with expertise in neuroimaging, blinded to clinical and MRI findings. Subjects were classified as negative, focal, or generalized PiB uptake, according to intensity and extent of cortical binding (figure). A positive PiB scan (PiBϩ) was defined by visual evidence of focal or generalized cortical PiB binding. Because CAA can affect the cerebellum, 30 we assessed for potential bias from cerebellar A␤ by repeating analyses with SUV normalized to the pons (SUVR pons ), and by comparing cerebellar SUVR pons between groups. The first subject has focal cortical A␤ deposition in the right temporo-occipital cortex, with a normal range neocortical standardized uptake value ratio (SUVR) of 1.49 (B). The second subject has extensive cortical A␤ (D) and a neocortical SUVR of 2.33. Both are asymptomatic healthy elderly subjects.
dance with published guidelines, and in order to avoid misclassification of calcification or diffuse iron deposition in the basal ganglia as MH, MH were identified as round or ovoid (nonlinear) hypointense lesions smaller than or equal to 10 mm (figure). Lesions were tracked through multiple slices to exclude pial blood vessels. 11 T1-and T2-weighted images were also available for correlation. All MRI were inspected blind to clinical and PiB scan findings. A consensus was obtained between 2 readers for the number and location of MH on each scan. Location was classified as lobar (LMHϩ, frontal, parieto-occipital, temporal, and cerebellar) or nonlobar (basal ganglia, brainstem). Cerebellar MH were grouped for analysis as lobar MH. The median time between PiB PET and MRI was 2 weeks.
Statistical analysis. Statistical analyses were performed using PASW Statistics SPSS version 18. Differences between groups were assessed with 2 , Fisher exact, or Student t tests. In HC participants, Pearson product moment was used to examine for correlation between number of LMH, age, and A␤ burden. Analysis was also performed with LMH by region and corresponding regional SUVR. All analyses were adjusted for demographic factors (age, gender, vascular risk factors, and antiplatelet use). Binary logistic regression was used to assess for independent predictors of presence of LMH. Data are presented as mean Ϯ SD unless otherwise stated.
RESULTS Sample demographics. Age, prevalence of vascular risk factors, and antiplatelet use did not differ significantly among the subjects with AD, subjects with MCI, and HC (table 1) . Two participants (1 HC, 1 MCI, neither with MH) were taking oral anticoagulation therapy (warfarin) and were included in analyses with those on antiplatelet medication.
All subjects with AD, 64.3% of subjects with MCI, and 34.5% of HC were PiBϩ ( 2 p Ͻ 0.05).
Microhemorrhage topography. MH were present in 37/138 subjects. The most common loci for MH were parieto-occipital (34.6%), frontal (32.1%), and temporal (13.6%), followed by cerebellar (9.9%), basal ganglia (7.4%), and brainstem (2.5%). There were no significant differences in the regional distribution of lesions between diagnostic groups. There was a trend to increased proportion of MH in posterior regions in PiBϩ compared with PiBϪ subjects, but this did not reach significance (data not shown). 
Four of 55 (7.3%) PiBϪ HC and 3 of 10 (30%) PiBϪ subjects with MCI were LMHϩ.
Participants with focal PiB retention. Two subjects with MCI and HC presented with focal PiB retention. Of these, 3 of 6 (50%) had LMH. LMH site corresponded to the region of increased PiB retention in 2 of these cases.
HCs with LMH. LMHϩ HC presented with higher global PiB retention (neocortical SUVR 1.7 Ϯ 0.5) than LMHϪ HC (1.3 Ϯ 0.3, p ϭ 0.01), and were significantly older (mean age 79.3 Ϯ 5.4 vs 73.5 Ϯ 6.9, p ϭ 0.001). While 66.7% of HC with 1 LMH were PiBϩ, the prevalence was higher (85.7%) in those participants with 2 or more LMH.
There was no significant difference in MMSE, vascular risk, APOE ⑀4 status, or antiplatelet use between LMHϩ HC and LMHϪ HC (table 2) .
HCs: Pearson correlations. Increasing age correlated with increasing neocortical SUVR (Pearson r ϭ 0.33, p ϭ 0.003, adjusted for gender). There was a significant correlation between age and number of LMH (r ϭ 0.32, p ϭ 0.03), and between neocortical SUVR and number of LMH (r ϭ 0.27, p ϭ 0.02).
There was also a strong correlation between parietooccipital LMH and parieto-occipital SUVR (r ϭ 0.28, p ϭ 0.01), but not between frontal LMH and frontal SUVR (r ϭ 0.09, p ϭ 0.43).
To examine for difference in regional distribution of A␤ between PiBϩ HC with and without LMH, we compared ratios of frontal:parieto-occipital (table 3) . Finally, in order to account for potential PiB retention in the cerebellar cortex, analyses were repeated with SUVR generated using the pons as reference region. Cerebellar SUVR pons was similar in HC, subjects with MCI, and subjects with AD (0.51 Ϯ 0.1, 0.50 Ϯ 0.1, and 0.52 Ϯ 0.1, respectively). There was also no significant difference in cerebellar PiB retention between HC with LMH (mean cerebellar SUVR pons 0.52 Ϯ 0.1) and those without LMH (0.50 Ϯ 0.1). There were 6 individu-als with cerebellar MH (2 PiBϩ HC, 1 PiBϪ MCI, 3 AD). Cerebellar PiB burden was not significantly higher in these individuals than in subjects with LMH in other areas (mean cerebellar SUVR pons 0.57 Ϯ 0.1 vs 0.52 Ϯ 0.1, p ϭ 0.2). DISCUSSION Using fine-slice, high-sensitivity SWI MRI, cerebral MH are a frequent finding in the cognitively normal elderly population. This study identified lobar MH in 30.8% of subjects with AD, 35.7% of subjects with MCI, and 19.1% of HC, slightly higher than previous reports of prevalence ranging from 12.5% to 32% in subjects with AD and 0% to 12% in HC. 10, 31, 32 The higher prevalence in our study may be the result of dissimilarities in demographics, the classification of MH, or the imaging protocol. SWI MRI thin-slice imaging provides better contrast and higher sensitivity for detection of MH, with up to threefold higher yield than conventional gradient echo MRI. 1 The prevalence of cortical 11 C-PiB retention reported here is well in agreement with previous reports, reflecting a continuum of increasing prevalence of cerebral A␤-burden with age in individuals without dementia. 33 However, as 11 C-PiB binds to A␤ deposits in both gray matter and vessel walls, 34 their relative contribution to the PET signal remains unclear. The majority of patients with AD have some degree of CAA, and about a quarter have extensive CAA at postmortem, 35 whereas in one study, one-fifth of subjects with CAA-associated hemorrhage (CAAH) at postmortem had no senile plaques. 36 Evidence suggests that even without plaques, 11 C-PiB scans are likely to be positive in CAA. 37, 38 Increased 11 C-PiB binding has been shown surrounding sites of MH on coregistered MRI, 27 and in 2 studies, global cortical 11 C-PiB retention in subjects with CAAH has been found to be in the middle range between HC and AD. 25, 24 In agreement with these reports, we found that LMHϩ HC presented with intermediate A␤ burden, with values in between those observed in LMHϪ HC and subjects with AD. However, without histopathologic correlation it is not clear if the 11 C-PiB binding in these subjects is attributable to vessel deposits, plaque, or both.
It has been suggested that the regional pattern of A␤ may separate the 2 processes. At postmortem, the occipital lobes appear frequently involved in cases of CAA, but are relatively less affected by neuritic plaques than other brain regions in AD. 39 These findings have been paralleled more recently using 11 C-PiB PET, with proportionally slightly higher occipital PiB retention (relative to global) in cases of probable CAA compared with AD. 24, 25 Our results in cognitively normal individuals are also consistent with these findings, with correlations between PiB retention and LMH in the parieto-occipital region, but not in the frontal area. There was also a trend to differing proportional PiB distribution (frontal: parieto-occipital) between PiBϩ HC with and without LMH, but this did not reach statistical significance.
In HCs, a positive PiB scan and increasing age were independent predictors of the presence of lobar MH, in a model including gender, APOE ⑀4 status, vascular risk factors, and antiplatelet therapy. While there were trends to higher prevalence of LMH among APOE ⑀4 carriers in our study, this did not reach significance, and APOE ⑀4 status was not a significant independent predictor of LMH in regression models. Although APOE ⑀4 may predispose to increased risk of CAA in the general population, 40 in this study it was the presence of A␤, rather than APOE ⑀4, that was of greater significance.
LMH were present in 31% to 41% of all PIBϩ subjects (AD, MCI, and HC), suggesting that the risk of LMH-and, as a consequence, symptomatic intracerebral bleeding-may be similarly increased in all PIBϩ individuals, irrespective of their clinical classification. These findings may ultimately have implications for stratification of antiplatelet, anticoagulant, and thrombolytic therapy in the wider community.
In a cohort of cognitively normal individuals with no prior history of cerebrovascular disease, 67% of participants with 1 LMH and 86% with 2 or more were PiBϩ. These results provide support for the use of the Boston Criteria for identification of CAA in this population.
In some AD anti-A␤ immunotherapy trials, individuals with MH are excluded due to the possibility of vascular complications such as vasogenic edema. 22 Our results show that 3-4 out of 10 individuals with high A␤ burden have LMH. Clear justification for exclusion of such patients from immunotherapy trials is essential as it may subsequently exclude a significant proportion of patients from this form of therapy.
This study has some limitations. First, our sample had a higher proportion of APOE ⑀4 carriers compared with the general population, and was largely composed of a middle-class, Caucasian demographic. As per the wider AIBL protocol, individuals with a history of ischemic stroke, ICH, or head injury were excluded, as well as those with a history of alcohol dependence. This, and a high proportion of treated vascular risk factors among the participants, may explain the lower prevalence of nonlobar MH in this study compared with some previous reports, 12 and limit applicability to wider, sociodemographically diverse populations. Second, while low-level vascular A␤ in the cerebellar cortex could affect SUVR measurements, we found no differences in the results of all analyses when repeated using the pons instead of the cerebellar gray matter as the reference region nor in cerebellar SUVR pons between participants with or without LMH.
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